Skip to main content


Figure 5 | BMC Cancer

Figure 5

From: Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS

Figure 5

Bevacizumab had no significant effects on Hewga-CCS cell growth. (A) Hewga-CCS cells were cultured in serum-containing medium in the absence or presence of 10, 50, 100, and 500 μg/mL of bevacizumab. The cell numbers were counted. Bars: SD. n.s.; not significant. (B) Nude mice were inoculated subcutaneously in the flank with 1 × 107 Hewga-CCS cells. When the tumors reached a palpable size, the mice were treated twice per week with intraperitoneal injection of 200 μg of bevacizumab or PBS, following which the tumor size was measured. Bars: SE. n.s.; not significant.

Back to article page